Proactive Investors - Run By Investors For Investors

Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria

The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit
Summit
Summit will present data on the antibiotics in Amsterdam next week

Summit Therapeutics PLC (LON:SUMM) is set to expand its drug portfolio with a new antibiotics series designed to fight bacteria responsible for infections of the bloodstream, lungs and urinary tract.

The company plans to present data on the series of new mechanism antibiotics, called DDS-04, at the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam on April 13-16.

READ: Summit Therapeutics well backed for next phase of development

The DDS-04 series targets Enterobacteriaceae, a family of Gram-negative bacteria that includes Klebsiella pneumoniae and Escherichia coli, which can cause severe and often deadly infections.

Summit said DDS-04 has shown activity across a panel of K.pneumoniae and E. coli strains, including strains resistant to the antibiotics currently available. 

“The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit. 

“We look forward to developing the programme to show compelling clinical and economic data that offer significant advantages over standard of care for the patients in need.”

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
1537236236_main-better-use.jpg
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use